Shots:

• Karyopharm to receive $75M up front & is eligible to receive ~$202.5M upon achievement of development & sales-based milestones along with royalties on net sales of Nexpovio
• Menarini gets a non-exclusive/exclusive license to develop & commercialize selinexor for Hematologic & oncology indications in the EU, UK, and other countries & also get non-exclusive license to package and label the product in/outside of the Territory for oncology indications
• Nexpovio is an oral SINE compound & is marketed as Xpovio in the US. Additionally, the EMA has validated the MAA for Nexpovio + Velcade & low-dose dexamethasone to treat MM while CHMP will review the MAA & is expected to be completed in H1’22

Ref: Karyopharm | Image: Karyopharm